Courtesy of Benzinga.
NuPathe Inc. (NASDAQ: PATH) today announced that the United States Patent and Trademark Office has issued a notice of allowance for U.S. Patent application 13/105,585 entitled “Transdermal Methods and Systems for the Delivery of Anti-Migraine Compounds.” This application relates to methods for effectively treating migraine in a patient using an iontophoretic patch containing a triptan without substantially irritating the patient’s skin. Given this action, NuPathe expects the patent to issue within the next few months. Once issued, the patent will provide additional protection for ZECUITY(R) and will be the fifth patent listed in the U.S. Food & Drug Administration’s (FDA) Orange Book. NuPathe has additional U.S. patents covering ZECUITY that expire between 2027 and 2029 and patent applications pending in the U.S. and other territories.
